Media stories about EyeGate Pharma (NASDAQ:EYEG) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. EyeGate Pharma earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.54742475792 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s scoring:
Shares of EYEG stock traded down $0.03 on Friday, hitting $0.36. The company’s stock had a trading volume of 14,699,128 shares, compared to its average volume of 1,225,057. EyeGate Pharma has a fifty-two week low of $0.29 and a fifty-two week high of $2.43. The company has a market capitalization of $6.61, a PE ratio of -0.35 and a beta of 3.58.
EyeGate Pharma (NASDAQ:EYEG) last released its quarterly earnings results on Friday, March 2nd. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. EyeGate Pharma had a negative net margin of 2,480.28% and a negative return on equity of 2,683.87%. equities research analysts anticipate that EyeGate Pharma will post -0.69 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on EYEG. HC Wainwright set a $5.00 price objective on shares of EyeGate Pharma and gave the company a “buy” rating in a report on Tuesday, December 19th. ValuEngine raised shares of EyeGate Pharma from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
TRADEMARK VIOLATION WARNING: “EyeGate Pharma (EYEG) Getting Somewhat Favorable Media Coverage, Analysis Shows” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/15/eyegate-pharma-eyeg-getting-somewhat-favorable-media-coverage-analysis-shows.html.
EyeGate Pharma Company Profile
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 treat non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body.
Receive News & Ratings for EyeGate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyeGate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.